Biomarkers for alzheimer's disease progression
A technology for Alzheimer's disease and disease, applied in biological testing, biomaterial analysis, drug combination, etc., can solve problems that cannot be cured and the etiology is not fully known
Image
Examples
Embodiment 1
[0159] Example 1. AFFYMETRIX 100K Genome Scan in Patients from the InDDEx Trial
[0160] [156] Introduction and Overview. The purpose of this example is to describe a genetic association study that identified 25 AD-associated mutations of the invention. Genome-wide analysis for genetic association studies has only become possible in the past two years. The Investigational Study of Delaying a Diagnosis of Alzheimer's Disease Using Exelon (InDDex; ENA713B IA07) clinical trial followed patients with MCI and administered either different doses of Exelon (rivastigmine) or placebo. agent and track its conversion to AD. The trial optionally had a DNA collection component, in which 442 samples were collected.
[0161] [157] To identify genetic variants that drive the conversion of MCI to AD, 420 patient samples from the InDDex (ENA713B IA07) clinical trial were analyzed using Haploview's case-control assay using the Affymetrix 100K gene assay at single loci and putative haplotype b...
PUM
Login to View More Abstract
Description
Claims
Application Information
- IPC
- A61K45/00; A61P25/28
- CPC
- A61K31/222; Y10T436/143333; A61P25/28; A61K45/00; G01N33/68
- Inventors
- J·BÂ·è¾›æ ¼
